Press monitoring

Safety upgrade found for gene-editing technique

18.11.2015   |   Press monitoring

A genome-editing method that could allow researchers to rapidly engineer entire populations has had an important upgrade. A US team has added safeguards to reduce the chances that such ‘gene drives’ will escape the laboratory, and found a way to erase the genetic mutations after they have spread. Gene drives hold the potential to wipe out...

Continue


European Medicines Agency approves Xiapex® for concurrent treatment of palpable cords

17.11.2015   |   Press monitoring

Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) today announced that the European Medicines Agency has approved Xiapex® (collagenase clostridium histolyticum, or CCH) for the treatment of two Dupuytren's contracture (DC) cords concurrently.

Continue


Bionor files first clinical trial application for BIOSKILL

17.11.2015   |   Press monitoring

Oslo, Norway, 17 November 2015 - Bionor Pharma ASA (OSE:BIONOR) today announced the submission of a clinical trial application (CTA) to the Danish Medicines Agency requesting approval to initiate BIOSKILL in Denmark. BIOSKILL ( BIO nor Shock and KILL ) will enroll patients internationally and further CTAs will be submitted to national medicines...

Continue


Scientists publish unique genomic discoveries with SMRT

16.11.2015   |   Press monitoring

A new paper released in Nature today reported the virtually complete draft genome of Oropetium thomaeum, a grass species that can regrow after exposed to extreme drought when water becomes available. The plant's 245 Mb genome was analyzed with 72x coverage on the PacBio RS II sequencing system by Donald Danforth Plant Science Center researchers...

Continue


Alcon introduces Contoura Vision as first personalized LASIK procedure at American Academy of Ophthalmology Annual Meeting

15.11.2015   |   Press monitoring

Basel, November 15, 2015 - Alcon, the global leader in eye care and a division of Novartis, will introduce Contoura Vision, the latest advancement in its WaveLight refractive portfolio during the annual meeting of the American Academy of Ophthalmology (AAO) in Las Vegas, November 14-17, 2015. Alcon will also present new research findings in...

Continue


IBA Signs Final Contracts to Install Three Compact Proton Therapy Centers in the United Kingdom

13.11.2015   |   Press monitoring

Louvain-la-Neuve, Belgium, November 13, 2015 - IBA (Ion Beam Applications S.A.), the world's leading provider of proton therapy solutions for the treatment of cancer, has signed contracts with Proton Partners International (PPI) to install three Proteus ® ONE compact proton therapy systems in private clinics in the United Kingdom: one in Newport...

Continue


Finnish Medicines Agency authorization of first-in-man clinical study with Lymfactin

13.11.2015   |   Press monitoring

Finnish Medicines Agency Fimea has authorized Herantis Pharma Plc's ("Herantis") first-in-man clinical study of Lymfactin® for the treatment of breast-cancer associated lymphedema. Patient recruitment in the clinical study is planned to begin in Finland in the first half of 2016.

Continue


Engineered bat virus stirs debate over risky research

13.11.2015   |   Press monitoring

An experiment that created a hybrid version of a bat coronavirus – one related to the virus that causes SARS (severe acute respiratory syndrome) – has triggered renewed debate over whether engineering lab variants of viruses with possible pandemic potential is worth the risks. In an article published in Nature Medicine, scientists investigated a...

Continue


Ekso Bionics(R) to Establish Headquarters in Freiburg, Germany; Strengthens European Expansion Efforts

12.11.2015   |   Press monitoring

RICHMOND, Calif., Nov. 12, 2015 (GLOBE NEWSWIRE) - Ekso Bionics Holdings, Inc. (OTCQB:EKSO), a leading global robotic exoskeleton company, announced today that it has established a new regional headquarters, based in Freiburg, Germany, to further strengthen its European presence and better serve German-speaking markets. The expansion is being led...

Continue


Navamedic to launch non-invasive prenatal tests in Nordic markets

12.11.2015   |   Press monitoring

Navamedic ASA (OSE: NAVA), the Norwegian medtech and pharmaceutical products company, announced today an agreement signed with Sequenom Laboratories of USA, a leading molecular diagnostics laboratory, for the launch of three non-invasive prenatal genetic tests in the Nordic region.

Continue


 

CEBIO

  • CEBIO
  • BC AV CR
  • Budvar
  • CAVD
  • CZBA
  • Eco Tend
  • Envisan Gem
  • Gentrend
  • JAIP
  • Jihočeská univerzita
  • Madeta
  • Forestina
  • ALIDEA

LinkedIn
TOPlist